VelaVigo

VelaVigo

Private
Hong Kong SARHealthcare & Life Scienceshttps://velavigo.com

Last Round

Early Funding

Jul 28, 2025

Total Funding Raised

$107M

Momentum Score

25 /100

Company Overview

VelaVigo is a biopharmaceutical company focused on researching and developing innovative drugs rooted in disease biology to create a seamless connection between drug discovery and clinical practice, ultimately providing patients with affordable, high-quality biological therapies.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

biologic drug discovery and developmentmulti-specific antibody discovery platformantibody-drug conjugate (ADC) development platformpreclinical drug candidate out-licensingfirst-in-class (FIC) biologic drug candidatesoncology and autoimmune disease therapeuticsbispecific antibody developmentbiopharmaceutical asset licensingbest-in-class (BIC) drug candidatesNectin4/TROP2 bispecific ADC

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

VelaVigo Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

VelaVigo Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Early FundingJul 28, 2025
VC RoundDec 31, 2024
AngelNov 15, 2021

VelaVigo Investors

Notable investors and investment history

InvestorRounds
Legend StarEarly Funding, VC Round
Shanghai Healthcare CapitalEarly Funding, VC Round
Zoo CapitalEarly Funding, VC Round
Highlight CapitalEarly Funding, VC Round
Northern Light Venture CapitalEarly Funding
Delian CapitalEarly Funding, VC Round
Trinity Innovation FundAngel

VelaVigo Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

VelaVigo Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about VelaVigo's valuation, stock price, and market status.

Firmographic Details

HeadquartersHong Kong SAR
Employee Range19
Year Founded2021
Last FundingJul 28, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.